Drugging the Matrix: Lysyl Oxidase Inhibitors to Tackle Scarring and Fibrosis
Molecular Horizons Seminar: Dr. Dieter Hamprecht
-
-
-
Wollongong Campus
28-101
Lysyl oxidases are a family of enzymes best known for their role in collagen crosslinking in extracellular matrix. The most visible manifestation of their aberrant activity is scarring of the skin. As part of our work to demonstrate the therapeutic potential of targeting these enzymes we have discovered and developed inhibitors of lysyl oxidases, some of which are now investigational drugs, allowing to test therapeutic concepts clinically.
An overview of the lysyl oxidase inhibitor (pan-LOX) drug discovery project will be given, with a focus on parameters relevant to the development of compounds for systemic use with oral administration, or local topical application, respectively. Preclinical as well as recent clinical data will be presented that support the therapeutic potential of pan-LOX inhibitors.